PRCT - PROCEPT BioRobotics gets FDA okay for prostate cancer study
2023-09-12 18:10:36 ET
More on Procept
- Seeking Alpha’s Quant Rating on Procept
- Historical earnings data for Procept
- Financial information for Procept
- Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy
- PROCEPT BioRobotics Corporation ( PRCT ) Q2 2023 Earnings Call Transcript
- Piper Sandler starts Procept at overweight, cites high growth potential
For further details see:
PROCEPT BioRobotics gets FDA okay for prostate cancer study